澤璟製藥(688266.SH):鹽酸傑克替尼片治療中高危骨髓纖維化的新藥上市申請審評在正常推進中
格隆匯6月1日丨有投資者向澤璟製藥(688266.SH)提問:公司鹽酸傑克替尼片治療中高危骨髓纖維化、重組人凝血酶的上市申請進展?
澤璟製藥回覆:鹽酸傑克替尼片治療中高危骨髓纖維化的新藥上市申請審評在正常推進中,目前已完成臨牀現場核查、製劑註冊核查以及原料藥的生產以及註冊二合一檢查工作。公司將積極與藥監部門開展溝通,爭取早日完成兩個藥品的註冊審評審批流程。
重組人凝血酶上市申請審評進展處於正常流程中,目前統計專業已經完成審評,並已完成臨牀現場核查、生產以及註冊二合一檢查工作,公司將積極與藥監部門開展溝通,爭取早日完成註冊審評審批流程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.